Personalized Peptide Vaccine in Advanced Pancreatic or Colorectal Cancer

Phase 1, open-label trial of synthetic tumor-associated peptide vaccine therapy in pancreatic ductal adenocarcinoma (PDAC) and colorectal adenocarcinoma (3 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Proportion of enrolled patients for whom a personalized vaccine is developed and ready to administer at 12 weeks, Proportion of enrolled patients who receive at least 1 dose of vaccine at any time post-enrollment at 44 weeks and 1 more. Started May 2016; status: active, not recruiting.